Patrizio Mario, Vago Valerio, Musumeci Marco, Fecchi Katia, Sposi Nadia Maria, Mattei Elisabetta, Catalano Liviana, Stati Tonino, Marano Giuseppe
Department of Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
J Mol Cell Cardiol. 2008 Dec;45(6):761-9. doi: 10.1016/j.yjmcc.2008.09.120. Epub 2008 Sep 25.
The treatment with beta-blockers causes an enhancement of the norepinephrine-induced fetal gene response in cultured cardiomyocytes. Here, we tested whether the activation of cAMP-mediated beta-adrenergic signaling antagonizes alpha(1)-adrenergic receptor (AR)-mediated fetal gene response. To address this question, the fetal gene program, of which atrial natriuretic peptide (ANP) and the beta-isoform of myosin heavy chain are classical members, was induced by phenylephrine (PE), an alpha(1)-AR agonist. In cultured neonatal rat cardiomyocytes, we found that stimulation of beta-ARs with isoproterenol, a beta-AR agonist, inhibited the fetal gene expression induced by PE. Similar results were also observed when cardiomyocytes were treated with forskolin (FSK), a direct activator of adenylyl cyclase, or 8-CPT-6-Phe-cAMP, a selective activator of protein kinase A (PKA). Conversely, the PE-induced fetal gene expression was further upregulated by H89, a selective PKA inhibitor. To evaluate whether these results could be generalized to Gq-mediated signaling and not specifically to alpha(1)-ARs, cardiomyocytes were treated with prostaglandin F(2)alpha, another Gq-coupled receptor agonist, which is able to promote fetal gene expression. This treatment caused an increase of both ANP mRNA and protein levels, which was almost completely abolished by FSK treatment. The capability of beta-adrenergic signaling to regulate the fetal gene expression was also evaluated in vivo conditions by using beta1- and beta2-AR double knockout mice, in which the predominant cardiac beta-AR subtypes are lacking, or by administering isoproterenol (ISO), a beta-AR agonist, at a subpressor dose. A significant increase of the fetal gene expression was found in beta(1)- and beta(2)-AR gene deficient mice. Conversely, we found that ANP, beta-MHC and skACT mRNA levels were significantly decreased in ISO-treated hearts. Collectively, these data indicate that cAMP-mediated beta-adrenergic signaling negatively regulates Gq cascade activation-induced fetal gene expression in cultured cardiomyocytes and that this inhibitory regulation is already operative in the mouse heart under physiological conditions.
β受体阻滞剂治疗可增强培养心肌细胞中去甲肾上腺素诱导的胎儿基因反应。在此,我们测试了cAMP介导的β肾上腺素能信号激活是否拮抗α(1)-肾上腺素能受体(AR)介导的胎儿基因反应。为解决这个问题,我们用苯肾上腺素(PE,一种α(1)-AR激动剂)诱导了以心房利钠肽(ANP)和肌球蛋白重链β异构体为经典成员的胎儿基因程序。在培养的新生大鼠心肌细胞中,我们发现用β-AR激动剂异丙肾上腺素刺激β-ARs可抑制PE诱导的胎儿基因表达。当心肌细胞用腺苷酸环化酶的直接激活剂福斯可林(FSK)或蛋白激酶A(PKA)的选择性激活剂8-CPT-6-Phe-cAMP处理时,也观察到了类似结果。相反,PE诱导的胎儿基因表达被选择性PKA抑制剂H89进一步上调。为评估这些结果是否能推广到Gq介导的信号传导而非特异性地针对α(1)-ARs,我们用前列腺素F(2)α(另一种Gq偶联受体激动剂,能够促进胎儿基因表达)处理心肌细胞。这种处理导致ANP mRNA和蛋白水平均升高,而FSK处理几乎完全消除了这种升高。我们还通过使用缺乏主要心脏β-AR亚型的β1和β2-AR双敲除小鼠,或通过给予亚升压剂量的β-AR激动剂异丙肾上腺素(ISO),在体内条件下评估了β肾上腺素能信号调节胎儿基因表达的能力。在β(1)和β(2)-AR基因缺陷小鼠中发现胎儿基因表达显著增加。相反,我们发现ISO处理的心脏中ANP、β-MHC和skACT mRNA水平显著降低。总体而言,这些数据表明,cAMP介导的β肾上腺素能信号在培养的心肌细胞中对Gq级联激活诱导的胎儿基因表达起负调节作用,并且这种抑制性调节在生理条件下的小鼠心脏中已经起作用。